NIU’s Global Round-up: Beneo’s new Brazilian application center, DuPont’s new BU, and more

03-Jun-2019 - Last updated on 03-Jun-2019 at 13:31 GMT

What's happened this week around the nutra-verse? Check out our weekly round-up of key news from across the globe.

LATAM

Beneo opens application center in São Paulo

Global ingredient supplier Beneo has opened its first regional application center in South America to provide a more localized approach to business and grow its market presence further, according to NutraIngredients-LATAM.

The regional application center in São Paulo, Brazil will focus on a wide range of applications, including dairy, bakery and savory.

Juliana Hirata, recently-appointed MD of Beneo Latin America, said Beneo is committed to growing presence in Latin America through focused efforts on a more regional approach; targeting on-trend product areas and global health trends; and maintaining strong investment in research and development.

“Beneo is clear in its commitment to science as the basis of nutritional or physiological benefits and therefore continues its investments in nutrition science; gaining more insight into how nutrition contributes to health for the long-term benefit of consumers,” she said.

Europe

DuPont creates Nutrition & Biosciences unit

DuPont has announced the creation of a new $6.3bn Nutrition & Biosciences business unit after merging its Nutrition & Health and Industrial Biosciences Businesses.

Headquartered in Copenhagen, Denmark, the new business will be spread across 70 manufacturing sites and 25 innovation centers worldwide.

“Combining the two businesses is a step to further accelerate growth and innovation while better providing customers across our industries with innovative, healthy, safe and sustainable solutions,” said Matthias Heinzel, the new unit’s new president.

The business unit will be split between three platforms, the business will focus on Food & Beverage, Health & Bioscience and Pharma Solutions.

For more about this, please click HERE.

Asia

Gencor eyes South East Asia and Taiwan after Levagen study boost

Following positive results from a clinical trial assessing the potential effects of Levagen on osteoarthritis, Gencor Pacific is eyeing success in South East Asia and Taiwan, according to NutraIngredients-Asia.

Levagen is a form of palmitoylethanolamide (PEA), known as an anti-inflammatory compound and pain reliever that protects against muscle deterioration. A recent study published in the journal Inflammopharmacology focused on osteoarthritis with the aim of being able to make health claims on nutraceuticals for healthy populations.

“We have conducted peer-reviewed and published toxicity, clinical, in vitro and animal studies, and we have a GRAS (generally recognised as safe) dossier for the US market for Levagen,” said RV Venkatesh, Gencor’s managing director.

“We are also trying to launch in Malaysia, Thailand, Vietnam, Indonesia and Taiwan, where we’ve had discussions with industry partners.

“In fact, our partner in Malaysia, and Pharmako in Australia, have taken the initiative to file the necessary paperwork on our behalf.”